mRNA-1273.529

BIOLOGICAL3 trials

Sponsors

ModernaTX, Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19SARS-CoV-2

Phase 2

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

CompletedNCT04927065

ModernaTX, Inc.SARS-CoV-2

Start: 2021-05-28End: 2023-11-17Updated: 2025-02-28

A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

CompletedNCT05249829

ModernaTX, Inc.SARS-CoV-2

Start: 2022-02-16End: 2023-06-23Updated: 2024-08-09

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

CompletedNCT05289037

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2022-03-30End: 2023-11-27Updated: 2025-10-17

Related Papers

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

Vaccine2025-09-09

P-102. Six-Month Safety, Durability, and Cross-Neutralization of the SARS-CoV-2 XBB.1.5-Containing Vaccine

Open Forum Infectious Diseases2025-01-29

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

2025-01-177 citations

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

Nature Communications2024-08-2931 citations

Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.

2023-12-0540 citations

2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial

Open Forum Infectious Diseases2023-11-271 citations

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Nature Medicine2023-08-3168 citations

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.

2023-08-2839 citations

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

2023-08-2320 citations

Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.

2023-06-1950 citations

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

2022-12-0532 citations

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.

2022-10-06121 citations

Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens

Frontiers in Immunology2022-10-0515 citations

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

New England Journal of Medicine2022-09-16635 citations

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

Vaccine X2022-08-297 citations